APEIRON Biologics AG

  • Land: Österreich

Nachricht vom 21.10.2019 | 15:00

APEIRON to present preclinical data at the 2019 AACR-NCI-EORTC Conference

DGAP-News: APEIRON Biologics AG / Key word(s): Conference

21.10.2019 / 15:00
The issuer is solely responsible for the content of this announcement.

APEIRON to present preclinical data at the 2019 AACR-NCI-EORTC Conference

Vienna, Austria, 21 October 2019: APEIRON Biologics AG, a biotechnology company developing breakthrough cancer immunotherapies with an approved product on the market, announced today that it will present preclinical data for its clinical stage project APN401 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 26-30 October 2019 in Boston, MA, USA.

Poster: C048 - Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior anti-tumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1

Anderson Gaweco 1, Kathrin Thell 1, Maria Urban 1, Julia Harrauer 1, Isabella Haslinger 1, Alexander Dohnal 1, Guenther Lametschwandtner 1, Karin Drobits 1, Romana
Gugenberger 1, Hannes Muehleisen 1, Josef Penninger 2, Carlos Becerra 3, Vincent Chung4, Anthony El-Khoueiry 5

1Apeiron Biologics; 2University of British Columbia; 3Baylor University Medical Center; 4City of Hope; 5USC Norris Comprehensive Cancer Center

Date: 29 October 2019
Session: Poster Session C: Therapeutic Agents-Other; 12:30 to 4:00pm
Room: Level 2, Hall D

About APEIRON Biologics AG
APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies. APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba(R)) in May 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights for this product to EUSA Pharma Ltd. APEIRON now leverages its proprietary master checkpoint blockade mechanism to enable the human body's natural defense mechanisms to fight the tumor. APEIRON's clinical lead program APN401 is a first-in-class autologous cellular therapy to strengthen immune reactivity via an intracellular master checkpoint, Cbl-b. APEIRON's projects and technologies are bolstered by a strong patent portfolio. APEIRON's development expertise is validated through partnerships with leading pharmaceutical companies and academic institutions.

For further information please contact:

APEIRON Biologics AG
Elis Karner, Investor and Public Relations
Email: investors@apeiron-biologics.com

Media and Investor Relations
MC Services AG
Raimund Gabriel
T +49 89 210 228 0
Email: apeiron@mc-services.eu

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

21.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)


Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Henkel AG & Co. KGaA: Henkel bestätigt Ausblick für das Geschäftsjahr 2019

14. November 2019, 07:30

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

SMT Scharf AG

Original-Research: SMT Scharf AG (von Montega AG): Kaufen

14. November 2019